Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis

Li, Yiqing; Tang, Ting; Xiao, Jie; Li, Boqi; Yang, Wenjuan; Xie, Shuangfeng; Du, Yumo; Huang, Kezhi; Nie, Danian

doi:10.1007/s00277-022-04840-9

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the induction treatment protocols A previous study has already indicated that the strategic selection of intensive chemotherapy regimens plays a significant role in achieving higher CR rates. 27 Moreover, the CRc rate of AML-RUNX1 mut showed no significant difference with AML-RUNX1 wt in our study.…”

Section: Discussioncontrasting

confidence: 52%

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis

Wang,

Li,

Jiang

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

This study aimed to investigate the clinical characteristics and prognosis of Runt‐related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML‐RUNX1mut) and 144 AML patients with wild‐type RUNX1(AML‐RUNX1wt) were selected using the case‐pair method(1:4). Compared to AML‐RUNX1wt, AML‐RUNX1mut showed higher frequency of ASXL1 (p < 0.001), SRSF2 (p < 0.001), BCORL1 (p < 0.001), RAS (p = 0.010) mutations, and absent NPM1 mutations (p = 0.022). The 3‐year overall survival (OS) and disease‐free survival (DFS) of AML‐RUNX1mut and AML‐RUNX1wt were 73.1% versus 68.0% (p = 0.64) and 80.7% versus 71.6% (p = 0.37), respectively. AML‐RUNX1mut receiving allogeneic hematopoietic cell transplantation (allo‐HSCT) showed better survival than those who did not receive allo‐HSCT (3‐year OS, 84.3% vs. 52.7%; p = 0.006). Multivariate analysis showed that EZH2 mutation (p = 0.003), white blood cell (WBC) ≥30 × 109/L (p = 0.036) and age ≥60 years (p = 0.038) were significant independent risk factors for inferior OS of AML‐RUNX1mut; WBC ≥30 × 109/L (p = 0.013) and DNMT3A mutation (p = 0.045) were significant independent risk factors for shorter DFS of AML‐RUNX1mut. In conclusion, AML‐RUNX1mut showed unique clinical characteristics, but the survival between AML‐RUNX1mut and AML‐RUNX1wt were comparable. EZH2 co‐mutation, DNMT3A co‐mutation, old age and high WBC count were associated with inferior survival of AML‐RUNX1mut. Allo‐HSCT can significantly improve the prognosis of AML‐RUNX1mut.

show abstract

Section: Discussioncontrasting

confidence: 52%

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis

Wang,

Li,

Jiang

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

show abstract

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia

Lian,

Zhuang,

et al. 2024

Hematology

View full text Add to dashboard Cite

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Xu,

Zhou,

Gong

et al. 2024

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: The response rate of traditional first-line induction chemotherapy (IC) for newly diagnosed acute myeloid leukemia needs to be improved, but it is not clear whether adding venetoclax or hypomethylating agents (HMAs) to IC will improve the response rate. Objective: To determine whether venetoclax or HMAs could increase the response rate of IC in patients with newly diagnosed acute myeloid leukemia (AML). Design: A retrospective, propensity score matching analysis. Methods: Newly diagnosed AML patients at Tongji Hospital between 2021 and 2023 were included in this study. By matching cases and controls based on age, gender, baseline bone marrow blast cell proportion, type of AML, and the National Comprehensive Cancer Network (NCCN) risk stratification group, we compared the response rate (CR, CR/CRi, ORR, and MRD negative) and hematological adverse events in newly diagnosed AML treated with IC plus venetoclax or HMAs versus IC alone after one cycle of IC. Results: The addition of venetoclax could improve CR/CRi of IC (83.8% for IC plus venetoclax vs 66.1% for IC alone, p = 0.029). The addition of venetoclax to IA regimen did not improve CR/CRi of IA regimen (76.9% for IA plus venetoclax vs 76.2% for IA alone, p = 0.986). The addition of HMAs could not only improves CR/CRi of IC (85.3%% for IC plus HMAs vs 65.4% for IC alone, p = 0.002) but also improves CR/CRi of IA regimen (91.3% for IA plus HMAs vs 70.0% for IA alone, p = 0.034). The addition of HMAs could improve CR/CRi of patients with adverse mutations (FLT3, IDH1/2, K/NRAS) after IC. The addition of venetoclax and HMAs both extended the duration of agranulocytosis and thrombocytopenia. Conclusion: Adding HMAs might improve CR/CRi of IC including IA. Adding venetoclax might not improve CR/CRi of IA. A well-designed prospective randomized controlled study is now warranted.

show abstract

Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis

Cited by 3 publications

References 40 publications

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Contact Info

Product

Resources

About